Search results
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 7 days agoGuselkumab has been approved in the EU to treat moderate to severe plaque psoriasis in adults who...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 7 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
Russell Investments Group Ltd. Has $283.28 Million Stock Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 6 days agoRussell Investments Group Ltd. lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.2% during the fourth quarter, according to the company in its most recent filing with the ...
Motley Fool Wealth Management LLC Cuts Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 6 days agoMotley Fool Wealth Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 11.1% during the fourth quarter, according to the company in its most recent ...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 5 days agoTremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic ...
Stokes Family Office LLC Has $11.14 Million Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 17 hours agoStokes Family Office LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 20.6% in the fourth quarter, according to the company in its most recent filing with ...